The state of New York currently has 20 active clinical trials seeking participants for Epilepsy research studies. These trials are conducted in various cities, including New York, Rochester, Bronx and Buffalo.
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures
Recruiting
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of idiopathic generalized epilepsy with generalized tonic-clonic seizures and includes an additional open-label extension (OLE) phase.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/14/2025
Locations: Dent Neurosciences Research Center, Amherst, New York +3 locations
Conditions: Generalized Epilepsy
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
Recruiting
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/11/2025
Locations: Dent Neurosciences Research Center, Amherst, New York +5 locations
Conditions: Focal Epilepsy
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
Recruiting
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/09/2025
Locations: Northwell Health, Great Neck, New York +1 locations
Conditions: Focal Epilepsy
FIH Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy
Recruiting
This clinical trial is designed to test whether a single image-guided intracerebral administration of inhibitory nerve cells, called interneurons (NRTX-1001), into subjects with drug-resistant unilateral mesial temporal lobe epilepsy (MTLE), with or without mesial temporal sclerosis (MTS), is safe (frequency of adverse events) and effective (seizure frequency). NRTX-1001 comprises human interneurons that secrete a neurotransmitter, gamma-aminobutyric acid (GABA).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/03/2025
Locations: NYU Langone Comprehensive Epilepsy Center, New York, New York +1 locations
Conditions: Mesial Temporal Lobe Epilepsy
Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits
Recruiting
Methylphenidate (MPH) is a stimulant, FDA-approved for the treatment of attention deficit hyperactivity disorder (ADHD). It is unknown, however, if stimulants would be of benefit for memory and thinking problems due to epilepsy. In this study, participants will be assigned randomly (i.e., by flip of a coin), to a group that takes MPH and a group that takes a placebo (sugar pill). Participants will not know the group to which they have been assigned. Tests of attention and memory will be complete... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2025
Locations: VA NY Harbor Healthcare System, New York, NY, New York, New York
Conditions: Epilepsy
An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures
Recruiting
An Open Label Clinical Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adult Patients With Focal Onset or Primary Generalized Tonic-Clonic Seizures
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/26/2025
Locations: Praxis Research Site, Middletown, New York
Conditions: Focal Onset Seizure, Primary Generalized Epilepsy
Telephone-Based Support Programs for People With Epilepsy
Recruiting
This is a two-arm randomized controlled trial to compare telephone-based depression self-management (UPLIFT) to telephone-based support groups (BOOST). A sample of 120 English- and Spanish-speaking people with epilepsy (PWE) with elevated depressive symptoms will be enrolled. Both interventions are 8-week programs delivered in one-hour weekly sessions to groups of about 6 participants. Changes in depressive symptoms, quality of life and seizures will be assessed over 12 months. The trial will al... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
03/24/2025
Locations: NYU Langone Health, New York, New York
Conditions: Epilepsy
Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures
Recruiting
Primary objective: To evaluate the safety and tolerability of cenobamate in pediatric subjects 2-17 years of age with partial-onset (focal) seizures
Gender:
ALL
Ages:
Between 2 years and 18 years
Trial Updated:
03/20/2025
Locations: Boston Children's Health Physicians - Neurology at Hawthorne, Hawthorne, New York
Conditions: Partial Epilepsy
Evaluation of the 24/7 EEG SubQ System for Ultra Long-Term Recording of Patients with Epilepsy Involving the Temporal Lobe Region.
Recruiting
The 24/7 EEG™ SubQ system will be compared to simultaneously recorded video-EEG in the Epilepsy Monitoring Unit (gold standard) and to self-reported seizure log books throughout 12 weeks of outpatient EEG recording. The present study is a 12-week open-label, prospective study with a paired, comparative design for pivotal evaluation of the safety and effectiveness of the 24/7 EEGTM SubQ system in subjects with epilepsy involving the temporal lobe region . 2-5 sites in Europe Up to 10 sites in U... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/10/2025
Locations: Northwell Health Department of Neurosurgery, Great Neck, New York
Conditions: Epilepsy
The Efficacy of a Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy
Recruiting
Ketamine is a medication that came into clinical practice in the 1960's. Ketamine is used as an anesthetic and to provide pain relief. Recently, Ketamine was approved to treat drug resistant depression using subanesthetic doses. In the hospital setting, intravenous anesthetic dosages are used to treat unrelenting seizures known as status epilepticus in comatose patients. Ketamine in subanesthetic doses has not been tried as a treatment for medication resistant seizures in the outpatient setting.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/12/2025
Locations: Mount Sinai Hospital, New York, New York
Conditions: Drug Resistant Epilepsy, Medically Refractory Epilepsy, Refractory Epilepsy
A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)
Recruiting
This is a multicenter, single arm, open label clinical trial that is designed to test the safety and preliminary efficacy of single administration inhibitory nerve cells called interneurons (NRTX-1001), into both temporal lobes of subjects with drug-resistant bilateral mesial temporal lobe epilepsy.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/11/2025
Locations: SUNY Upstate Medical University, Syracuse, New York
Conditions: Epilepsy, Temporal Lobe
Prediction of Anxiety and Memory State
Recruiting
The purpose of this study is to look at how signals in the brain, body, and behavior relate to anxiety and memory function. This project seeks to develop the CAMERA (Context-Aware Multimodal Ecological Research and Assessment) platform, a state-of-the-art open multimodal hardware/software system for measuring human brain-behavior relationships. The R61 portion of the project is designed to develop the CAMERA platform, which will use multimodal, passive sensor data to predict anxiety-memory stat... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
01/16/2025
Locations: Columbia University, New York, New York
Conditions: Anxiety, Memory, Epilepsy